Letter From The Editor

This week in Part 4 of our Homerun Slides series, Dr. Schwartz finishes up by looking at the treatments for LADA, MODY, type 1 and type 2 diabetes, and makes a case for using medications that replace or enhance incretin availability. He even delves into the idea of treating pre-diabetes …

I am sure many of you have received an email or Facebook post to participate in the ALS Ice Bucket Challenge. I am amazed by the number of people who will actually have a bucket of ice poured over their heads, yet will not take the time to check their …

MODY, cystic fibrosis, and Wolfram syndrome all have something in common. Believe it or not, they are all a form of diabetes. This week, our Clinical Text from the Handbook of Diabetes looks at these and other types or non-traditional causes of diabetes. Our Homerun Slides focus on how to …

Recently JARDIANCE (Empagliflozin) was approved for use, making it the third in this new class of medications. The first two, Invokana (canagiflozin) and Farxiga (dapagliflozin), have had relatively good acceptance into the marketplace especially with the financial ease they have established to get patients to use the medication. There are …

It is always interesting when two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes. Our own advisory board endocrinologist, Stanley Schwartz, is a good …

  Sanofi is expanding its insulin portfolio to include the new inhaled insulin, Affreza. While it may not perform in the market at the scale of Lantus, I, for one, am glad that Sanofi is doing this. Five years ago a small company called VeroScience came out with a new …

Sometimes when we prepare this newsletter, the articles, slides and text all seem to go together. That is very evident when we look at the Clinical Text from Drs. Rudy Bilous and Richard Donnelly, as they talk about the epidemiology of type 2 diabetes. This week, they delve into a lot …

For years we have had methods for titrating patients with long-acting insulin and there have been very successful patient self-titration algorithms that have proven to work as well as physician-directed dosing. The problem has always been what to do when we need to begin mealtime insulin. Since the use of …

Steve, Andrew and I are at the AADE Annual Meeting in Orlando. This meeting has a different flavor than some of the other meetings that we report on. While there are many clinical studies and new drug discoveries presented at the ADA and IDF Scientific Sessions, the AADE meeting is …

Last week I started two patients on V-GO devices. For those of you who are not familiar with the device it is a simple mechanical (not electrical) device that can deliver a basal of 20, 30, or 40 units of insulin a day and allow your patients to deliver up …